105 related articles for article (PubMed ID: 15189174)
1. Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results.
Zoungas S; Branley P; Kerr PG; Ristevski S; Muske C; Demos L; Atkins RC; Becker G; Fraenkel M; Hutchison BG; Walker R; McNeil JJ; McGrath BP
Nephrology (Carlton); 2004 Jun; 9(3):130-41. PubMed ID: 15189174
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial.
Zoungas S; McGrath BP; Branley P; Kerr PG; Muske C; Wolfe R; Atkins RC; Nicholls K; Fraenkel M; Hutchison BG; Walker R; McNeil JJ
J Am Coll Cardiol; 2006 Mar; 47(6):1108-16. PubMed ID: 16545638
[TBL] [Abstract][Full Text] [Related]
3. Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD.
Zoungas S; Cameron JD; Kerr PG; Wolfe R; Muske C; McNeil JJ; McGrath BP
Am J Kidney Dis; 2007 Oct; 50(4):622-30. PubMed ID: 17900462
[TBL] [Abstract][Full Text] [Related]
4. Arterial function after successful renal transplantation.
Zoungas S; Kerr PG; Chadban S; Muske C; Ristevski S; Atkins RC; McNeil JJ; McGrath BP
Kidney Int; 2004 May; 65(5):1882-9. PubMed ID: 15086931
[TBL] [Abstract][Full Text] [Related]
5. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
6. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
Vianna AC; Mocelin AJ; Matsuo T; Morais-Filho D; Largura A; Delfino VA; Soares AE; Matni AM
Hemodial Int; 2007 Apr; 11(2):210-6. PubMed ID: 17403173
[TBL] [Abstract][Full Text] [Related]
7. Rationale and design of the Folic Acid for Vascular Outcome Reduction In Transplantation (FAVORIT) trial.
Bostom AG; Carpenter MA; Kusek JW; Hunsicker LG; Pfeffer MA; Levey AS; Jacques PF; McKenney J;
Am Heart J; 2006 Sep; 152(3):448.e1-7. PubMed ID: 16923411
[TBL] [Abstract][Full Text] [Related]
8. [The role of hyperhomocysteinemia on atherosclerosis in patients with chronic renal failure].
Yu Y; Hou F; Zhou H; Yang Y; Zhang X; Yang L; Hu M
Zhonghua Nei Ke Za Zhi; 2002 Aug; 41(8):517-21. PubMed ID: 12421497
[TBL] [Abstract][Full Text] [Related]
9. Serum homocysteine, folate, vitamin B12 levels and arterial stiffness in diabetic patients: which of them is really important in atherogenesis?
Shargorodsky M; Boaz M; Pasternak S; Hanah R; Matas Z; Fux A; Beigel Y; Mashavi M
Diabetes Metab Res Rev; 2009 Jan; 25(1):70-5. PubMed ID: 19065546
[TBL] [Abstract][Full Text] [Related]
10. Folic acid 5 or 15 mg/d similarly reduces plasma homocysteine in patients with moderate-advanced chronic renal failure.
Bernasconi AR; Liste A; Del Pino N; Rosa Diez GJ; Heguilén RM
Nephrology (Carlton); 2006 Apr; 11(2):137-41. PubMed ID: 16669976
[TBL] [Abstract][Full Text] [Related]
11. Effect of multivitamin supplementation on the homocysteine and methylmalonic acid blood concentrations in women over the age of 60 years.
Wolters M; Hermann S; Hahn A
Eur J Nutr; 2005 Mar; 44(3):183-92. PubMed ID: 15309436
[TBL] [Abstract][Full Text] [Related]
12. [Hyperhomocysteinemia, oxidative stress and microinflammation in chronic renal failure: their roles in atherogene].
Yu YM; Hou FF; Zhang X; Zhou H; Liu ZQ
Zhonghua Nei Ke Za Zhi; 2004 Apr; 43(4):292-5. PubMed ID: 15130417
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine and its determinants in nondialyzed chronic kidney disease patients.
Nerbass FB; Draibe SA; Feiten SF; Chiarello PG; Vannucchi H; Cuppari L
J Am Diet Assoc; 2006 Feb; 106(2):267-70. PubMed ID: 16442876
[TBL] [Abstract][Full Text] [Related]
14. Homocysteine is not associated with arterial thickness and stiffness in healthy middle-aged French volunteers.
de Bree A; Mennen LI; Zureik M; Ducros V; Guilland JC; Nicolas JP; Emery-Fillon N; Blacher J; Hercberg S; Galan P
Int J Cardiol; 2006 Nov; 113(3):332-40. PubMed ID: 16364473
[TBL] [Abstract][Full Text] [Related]
15. Pulse wave velocity--a useful tool for cardiovascular surveillance in pre-dialysis patients.
Lemos MM; Jancikic AD; Sanches FM; Christofalo DM; Ajzen SA; Miname MH; Santos RD; Fachini FC; Carvalho AB; Draibe SA; Canziani ME
Nephrol Dial Transplant; 2007 Dec; 22(12):3527-32. PubMed ID: 17704115
[TBL] [Abstract][Full Text] [Related]
16. Homocysteine and carotid atherosclerosis in chronic renal failure--the confounding effect of renal function.
Leskinen Y; Lehtimäki T; Loimaala A; Huhtala H; Salenius JP; Oja SS; Saha H
Atherosclerosis; 2004 Aug; 175(2):315-23. PubMed ID: 15262188
[TBL] [Abstract][Full Text] [Related]
17. Association of pulse pressure with carotid atherosclerosis in patients with type 2 diabetes mellitus.
Wakabayashi I; Masuda H
Blood Press; 2007; 16(1):56-62. PubMed ID: 17453753
[TBL] [Abstract][Full Text] [Related]
18. Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure.
Chauveau P; Chadefaux B; Coudé M; Aupetit J; Kamoun P; Jungers P
Miner Electrolyte Metab; 1996; 22(1-3):106-9. PubMed ID: 8676798
[TBL] [Abstract][Full Text] [Related]
19. Pulse wave velocity and coronary risk stratification.
Mendonça MI; Reis RP; Sousa AC; Gomes S; Faria P; Pereira A; Silva B; Serrão M; Santos N; Sousa FS; Silva JA; Sousa J; Ornelas I; Freitas S; Cardoso A; Araújo JJ
Rev Port Cardiol; 2009 Feb; 28(2):155-71. PubMed ID: 19438151
[TBL] [Abstract][Full Text] [Related]
20. Short-term oral folic acid supplementation enhances endothelial function in patients with type 2 diabetes.
Mangoni AA; Sherwood RA; Asonganyi B; Swift CG; Thomas S; Jackson SH
Am J Hypertens; 2005 Feb; 18(2 Pt 1):220-6. PubMed ID: 15752950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
